Proteomic profiling of peritoneal rinse fluid sediment separates patients with ovarian cancer from women admitted for cesarean section. A pilot study

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49.
   PubMed Web of Science ®Google Scholar
• Menon U. Ovarian cancer screening. CMAJ 2004;171: 323–4.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange proteinchips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343–8.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast RC, Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882–90.
   PubMed Web of Science ®Google Scholar
• Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432–41.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–7.
   PubMed Web of Science ®Google Scholar
• Rai AJ, Zhang Z, Rosenzweig J, Shih Ie M, Pham T, Fung ET, Sokoll LJ, Chan DW. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002;126:1518–26.
   PubMed Web of Science ®Google Scholar
• Yu JK, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B 2005;6:227–31.
   PubMedGoogle Scholar
• Jurisicova A, Jurisica I, Kislinger T. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev Proteomics 2008;5:551–60.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5: 4589–96.
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–67.
   PubMed Web of Science ®Google Scholar
• Honoré B, Østergaard M, Vorum H. Functional genomics studied by proteomics. Bioessays 2004;26:901–15.
   PubMed Web of Science ®Google Scholar
• Honoré B, Vorum H, Pedersen AE, Buus S, Claësson MH. Changes in protein expression in p53 deleted spontaneous thymic lymphomas. Exp Cell Res 2004;295:91–101.
   PubMed Web of Science ®Google Scholar
• Lyngholm M, Vorum H, Nielsen K, Østergaard M, Honoré B, Ehlers N. Differences in the protein expression in limbal versus central human corneal epithelium – a search for stem cell markers. Exp Eye Res 2008;87:96–105.
   PubMed Web of Science ®Google Scholar
• Østergaard M, Hansen GAW, Vorum H, Honoré B. Proteomic profiling of fibroblasts reveals a modulating effect of extracellular calumenin on the organization of the actin cytoskeleton. Proteomics 2006;6:3509–19.
   PubMed Web of Science ®Google Scholar
• Honoré B, Buus S, Claësson MH. Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53. Proteome Sci 2008;6:18.
   PubMed Web of Science ®Google Scholar
• Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20:3551–67.
   PubMed Web of Science ®Google Scholar
• Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 2007;29:92–110.
   PubMed Web of Science ®Google Scholar
• Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum ca-125? Am J Obstet Gynecol 2008;199: 215–23.
   PubMed Web of Science ®Google Scholar
• Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904–11.
   PubMed Web of Science ®Google Scholar
• Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE. Phase ii biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010;136:1079–88.
   PubMed Web of Science ®Google Scholar
• Walsh CS, Karlan BY. Molecular signatures of ovarian cancer: from detection to prognosis. Mol Diagn Ther 2010;14:13–22.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005;5:4625–36.
   PubMed Web of Science ®Google Scholar
• Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370–9.
   PubMed Web of Science ®Google Scholar
• Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010;31:599–610.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Heppelmann CJ, Charlesworth MC, Madden BJ, Miller MN, Kalli KR, Cilby WA, Bergen HR, 3rd, Saggese DA, Muddiman DC. Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res 2006;5:3318–25.
   PubMed Web of Science ®Google Scholar
• Khan A, Packer NH. Simple urinary sample preparation for proteomic analysis. J Proteome Res 2006;5:2824–38.
   PubMed Web of Science ®Google Scholar
• Kang S, Shim HS, Lee JS, Kim DS, Kim HY, Hong SH, Kim PS, Yoon JH, Cho NH. Molecular proteomics imaging of tumor interfaces by mass spectrometry. J Proteome Res 2010;9:1157–64.
   PubMed Web of Science ®Google Scholar
• Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, Lee S, Lee C, Ko JJ, An HJ. Proteomic identification of overexpressed prdx 1 and its clinical implications in ovarian carcinoma. J Proteome Res 2010;9:451–7.
   PubMed Web of Science ®Google Scholar
• Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St Onge P, Kireeva I, Schmitt-Ulms G, Brown TJ, Murphy J, Rosen B, Shaw P, Jurisica I, Kislinger T. A proteome resource of ovarian cancer ascites: Integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008;7:339–51.
   PubMed Web of Science ®Google Scholar
• Jandu N, Richardson M, Singh G, Hirte H, Hatton MW. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Int J Gynecol Cancer 2006;16:1536–44.
   PubMed Web of Science ®Google Scholar
• Gericke B, Raila J, Sehouli J, Haebel S, Konsgen D, Mustea A, Schweigert FJ. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005;5:133.
   PubMed Web of Science ®Google Scholar
• Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med 2001;161:2733–7.
   PubMedGoogle Scholar
• Zhao C, Annamalai L, Guo C, Kothandaraman N, Koh SC, Zhang H, Biswas A, Choolani M. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 2007;9:1–7.
   PubMed Web of Science ®Google Scholar
• Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885–91.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7.
   PubMed Web of Science ®Google Scholar
• Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, Camp DG, 2nd, Smith RD. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006;5: 2167–74.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of n-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660–6.
   PubMed Web of Science ®Google Scholar